KOSDAQBiotech & Pharma196170

Alteogen

₩171,100▼ 1.10%2026-11-18 close
Market Cap
₩11.9T
Turnover
₩40B
Volume
230K
Shares out.
69.7M
PER
51.9×
PBR
—
EPS
₩3,352
Dividend Yield
0.21%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩371 per share · Prices as of the 2026-11-18 close

01

Report overview

Royalty income drives profit; next deals are the test

Alteogen turned profitable in 2024 on ALT-B4 platform income, posted KRW 106.9 billion in operating profit in 2025, and reported KRW 78.9 billion in the 2026 third quarter. The next test is whether new licensing deals keep coming and how US drug-pricing terms affect royalty income.

  1. 1

    Operating profit reached KRW 106.9 billion in 2025, up 320.8% year on year, and the operating margin rose to 49.5%.

  2. 2

    In 2026, ALT-B4 deals were disclosed in sequence with Tesaro (a GSK subsidiary, for a subcutaneous dostarlimab formulation), Biogen (two products), and an undisclosed global pharma partner.

  3. 3

    Securities analysts attribute the third-quarter revenue of KRW 119.8 billion and operating profit of KRW 78.9 billion to Qlex sales milestones and fees from new licensing contracts.

  4. 4

    Because income is weighted toward royalties and milestones, results are sensitive to partner product sales and US drug-pricing policy, which is cited as a bearish factor.

  5. 5

    Broker target prices vary widely, with Daishin Securities at KRW 450,000 (November 2026), Shinhan Investment at KRW 430,000 and IBK Securities at KRW 320,000 among those reported. The next periodic filing is the 2026 annual report.

02

Business structure

Alteogen is built around its Hybrozyme platform, which converts intravenous (IV) drugs into subcutaneous (SC) formulations. Its core asset is the recombinant hyaluronidase ALT-B4, which temporarily breaks down hyaluronan in subcutaneous tissue so drugs are absorbed faster.

Revenue comes mainly from partner upfront payments, milestones and royalties tied to net sales, rather than from its own product sales. As of the company's January 2026 disclosure, it had three commercialized products: the subcutaneous Keytruda formulation Qlex developed with MSD, a Herceptin biosimilar, and Tergase.

According to Hana Securities, Qlex sales rose 79.3% quarter on quarter in the third quarter of 2026, and Qlex's share of total Keytruda sales reached 9.7%, up 3.8 percentage points.

Partners now include MSD, Sandoz, Daiichi Sankyo, AstraZeneca and GSK, and in 2026 Tesaro (a GSK subsidiary), Biogen and an undisclosed global pharma company were added.

The main competitor is Halozyme, whose Enhanze technology targets the same SC conversion market, and the two companies have been in US patent disputes. In June 2026 the company said the US PTAB dismissed a Halozyme inter partes review challenge against it.

The company says it is extending ALT-B4 into ADCs, RNA therapeutics and bispecific antibodies, and it takes part in developing Daiichi Sankyo's Enhertu SC.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩49B₩26.7B54.4%
2025Q4₩64.5B₩19.6B30.4%
2026Q1₩71.6B₩39.3B54.9%
2026Q2₩68.9B₩34.2B49.6%
2026Q3₩119.8B₩78.9B65.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩28.8B-₩29.4B-₩10.1B−102.0%−6.8%68.9%
2023₩96.5B-₩9.7B-₩3.6B−10.1%−2.4%73.2%
2024₩102.9B₩25.4B₩60.7B24.7%22.2%49.2%
2025₩215.9B₩106.9B₩141.7B49.5%31.8%53.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 28.8 billion in 2022 to KRW 96.5 billion in 2023 (up 235.1% year on year), then KRW 102.9 billion in 2024 (up 6.6%) and KRW 215.9 billion in 2025 (up 109.9%). Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year in the 2022-2025 period.

Operating results moved from an operating loss of KRW 29.4 billion in 2022 and an operating loss of KRW 9.74 billion in 2023, where losses narrowed, to operating profit of KRW 25.4 billion in 2024, a turn to profit. Operating profit in 2025 was KRW 106.9 billion, up 320.8% year on year.

The operating margin moved from -102.0% in 2022 and -10.1% in 2023 to 24.7% in 2024 and 49.5% in 2025, so profit grew faster than revenue.

Net income attributable to controlling shareholders went from a loss of KRW 10.1 billion in 2022 and a loss of KRW 3.58 billion in 2023 to KRW 60.7 billion in 2024, a turn to profit, and KRW 141.7 billion in 2025, up 133.4%.

Net income including non-controlling interests was KRW 145.2 billion in 2025, a different figure from net income attributable to controlling shareholders. At the end of 2025, total equity was KRW 454.4 billion (KRW 445.2 billion attributable to controlling shareholders) and total liabilities were KRW 244.3 billion.

The debt ratio edged up from 49.2% in 2024 to 53.8% in 2025. Operating cash flow went from negative KRW 17.9 billion in 2022 and negative KRW 7.77 billion in 2023 to KRW 53 billion in 2024, a turn to positive, and KRW 124.1 billion in 2025.

Quarterly revenue was KRW 49 billion in the third quarter of 2025, KRW 64.5 billion in the fourth quarter (up 31.6% quarter on quarter), KRW 71.6 billion in the first quarter of 2026 (up 11.0%), KRW 68.9 billion in the second quarter (down 3.8%) and KRW 119.8 billion in the third quarter (up 73.9%).

Operating profit was KRW 26.7 billion in the third quarter of 2025, KRW 19.6 billion in the fourth quarter (down 26.4%), KRW 39.3 billion in the first quarter of 2026, KRW 34.2 billion in the second quarter (down 13.0%) and KRW 78.9 billion in the third quarter (up 130.8% quarter on quarter and 195.8% year on year).

For the third-quarter revenue jump, Daishin Securities points to Qlex sales milestones and new licensing contracts, and estimates third-quarter technology fee income at about KRW 110 billion.

Net income attributable to controlling shareholders of KRW 71.7 billion in the first quarter of 2026 exceeded that quarter's operating profit of KRW 39.3 billion, which suggests non-operating items may have weighed significantly.

Later quarters were KRW 28.4 billion in the second quarter (down 60.4%) and KRW 43 billion in the third quarter (up 51.2%), so the quarterly swings are large. Net income attributable to controlling shareholders over the last four quarters (fourth quarter of 2025 through third quarter of 2026) totaled KRW 214 billion.

05

Industry analysis

Korea's biotech sector was described as relatively sidelined in 2026 as capital flowed toward semiconductors and robotics.

By contrast, Korean biotech licensing deals totaled about KRW 11.5 trillion in the first half of 2026, which exceeded the full-year 2025 total of about KRW 7.5 trillion in the first half, and reports said the amount had returned to the KRW 10 trillion range for the first time since 2021.

Alteogen's CEO said in June 2026 that subcutaneous conversion is becoming an industry-wide trend, driven by patent-expiry planning and patient convenience. In competition, Halozyme's Enhanze targets the same subcutaneous formulation market.

In a July 2026 report, Hana Securities argued that biosimilars using the same enzyme as Enhanze would have little product differentiation, while ALT-B4 could differentiate on enzyme performance.

Right after the January 2026 GSK deal, an industry source said Alteogen has so far signed only for targets that Halozyme has licensed exclusively, which limits the addressable market.

On November 9, 2026, shares of the KOSDAQ market-cap leader fell 16% on reports of tighter US drug-pricing rules and European patent dispute concerns.

Among listed peers, Celltrion and Samsung Biologics are tied more closely to manufacturing scale, whereas Alteogen's platform royalty model depends more on partners' clinical and approval progress. The company says it is gradually building GMP-level in-house production capacity.

06

Outlook

The company has set a medium-term goal of raising its commercial products from three today to nine or more by 2030, as presented at the JP Morgan Healthcare Conference in January 2026.

The same roadmap said partner products that clear approvals in each country would bring the cumulative number of commercialized products to six or more by year-end. European launch and commercialization of Eylea biosimilar Aileusi was also presented as a 2026 priority.

Interim phase 1 results for Enhertu SC were previewed for the second half of 2026, and analysts said they could catalyze further ADC licensing deals. AstraZeneca's Imfinzi SC phase 1 results were also cited as a key variable.

On the timing of Qlex sales milestones, Daishin Securities and IBK Securities expect full receipt by 2028, while Hana Securities flagged the possibility of later receipt.

Daishin Securities estimates that US price cuts could reduce Qlex net sales and linked royalties by 3-10%, with a low-single-digit percentage effect on Alteogen's total revenue.

Hana Securities expects 2026 operating profit to exceed KRW 300 billion and estimates KRW 593.3 billion in 2027 revenue and KRW 406.3 billion in 2027 operating profit, in a third-quarter 2026 report. The next periodic filing, the 2026 annual report, will show full-year results and the quarterly trend.

07

Valuation

PER
51.9×
PBR
—
ROE
46.7%
EPS
₩3,352
BPS
—
Dividend per share
₩371

Broker target prices vary widely across reports. Daishin Securities presented a target price of KRW 450,000 in a report dated November 4, 2026.

Shinhan Investment was reported in November 2026 to have lowered its target to KRW 430,000, and IBK Securities cut its target to KRW 320,000 to reflect lower long-term profitability from drug-price cuts.

Hana Securities lowered its target multiple after peer valuations fell following its third-quarter 2026 results, cutting its target from KRW 450,000 to KRW 410,000, and applied a 25% discount to its valuation given the dependence on the ALT-B4 business.

Earnings scale has grown since the turn to profit in 2024, but the share price has declined in 2026. The dividend yield is below the industry average, and market capitalization is at a large premium to total equity at the end of 2025.

Lower peer valuation levels and the Qlex pricing variable are cited as common reasons behind the target cuts. Because estimates shift with the timing of milestone receipts, that timing is the key variable in interpreting valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Margin gains from a royalty-led model

The operating margin rose from 24.7% in 2024 to 49.5% in 2025, and third-quarter 2026 operating profit of KRW 78.9 billion was up 195.8% year on year. Daishin Securities views the royalty and milestone structure as accelerating margin improvement. Royalty income is set to grow alongside partner product sales.

More deals and wider modality coverage

Three deals were announced in 2026 with Tesaro, Biogen and an undisclosed partner. The company says it keeps material transfer agreements with roughly ten global pharma companies for follow-on talks. CEO Jeon Tae-yeon says the platform's reach is expanding to ADCs, RNA therapies and bispecific antibodies.

Easing patent-dispute pressure

The company says the US PTAB dismissed a Halozyme challenge to its process patent, allowing it to defend the position. No post-grant challenge has been filed against the ALT-B4 substance patent in the US, which the company says eased market concern. It adds that partners have rarely raised patent questions in recent talks.

09

Bear factors

Dependence on US drug pricing and Keytruda SC sales

Qlex sales are the core source of earnings, so US drug-pricing policy is a direct variable. Reports said shares fell 16% on November 9, 2026 on tighter US pricing rules and European patent dispute concerns. IBK Securities cut its target on the view that price cuts could weigh on long-term profitability.

Limited deal scope and questions on scalability

Right after the January 2026 GSK deal, an industry source said Alteogen has been signing mainly for targets exclusively licensed to Halozyme, which could limit the addressable market. That concern ties to the view that proving platform scalability remains a challenge. The company, by contrast, describes its reach as widening into ADCs, RNA therapies and bispecific antibodies.

High quarter-to-quarter volatility

Second-quarter 2026 revenue of KRW 68.9 billion fell 3.8% quarter on quarter, and net income attributable to controlling shareholders fell 60.4% to KRW 28.4 billion. Third-quarter revenue and operating profit jumped, but because fee income tends to cluster in particular quarters, quarterly swings can be large. This makes trend reading from single quarters difficult.

10

Risk factors

Policy and drug pricing

Tighter US drug-pricing rules are a variable for the unit economics of Qlex royalties. Daishin Securities estimates Qlex net sales and linked royalties could fall 3-10%, but sees a low-single-digit effect on total company revenue. IBK Securities reflected price cuts as a long-term profitability drag in its target.

Patents and competition

A March 2026 report said the outcome of Halozyme's US PTAB challenge against its MDASE platform could mark a turning point in the patent dispute. Hana Securities flagged the possibility of biosimilar developers using the same enzyme. Depending on how patent rulings go, partner terms and royalty expectations could shift.

Milestone timing and flows

Forecasts diverge on when Qlex sales milestones will be fully received. Hana Securities flagged possible delays, while Daishin and IBK expect full receipt by 2028. A January 2026 report named passive fund selling and capital rotation toward semiconductors and robotics as downward pressure on shares.

11

What to watch next

  1. By late December 2026

    Whether interim phase 1 results for Enhertu SC are released as previewed for the second half. They bear directly on expectations for additional ADC licensing.

  2. End of December 2026

    Whether partner approvals and launches bring cumulative commercialized products to six or more. This is the year-end checkpoint on the roadmap the company presented.

  3. End of March 2027 (statutory deadline for the annual report)

    Full-year 2026 revenue, operating profit and operating cash flow in the annual report, plus fourth-quarter results. The fourth quarter of 2026 has not yet been filed and will first be confirmed in this report.

  4. Around May 2027 (expected timing of first-quarter 2027 results)

    The size of Qlex sales milestones recognized and whether price cuts are reflected. This will indicate whether the full-receipt-by-2028 view or the delay scenario is closer.

12

Overall view

Royalty and fee income from the ALT-B4 platform lifted Alteogen's results, moving operating profit from a loss of KRW 29.4 billion in 2022 to KRW 106.9 billion in 2025. Three licensing deals followed in 2026, and third-quarter revenue reached KRW 119.8 billion.

Because income is tied to partner product sales and milestone timing, quarterly swings are large. Bullish factors include more deals, progress in defending patents and a 49.5% operating margin, while bearish factors include US drug-pricing rules, questions about the limited scope of deals and possible milestone delays.

Broker target prices diverge widely, depending heavily on pricing and milestone assumptions. The next checkpoints are the 2026 annual report's full-year operating margin, commercialization progress of partner products, and phase 1 results for Enhertu SC. This report does not present an investment opinion, a rating or a target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.news.nate.com
  2. mt.co.kr
  3. news.nate.com
  4. news.nate.com
  5. news.nate.com
  6. greened.kr
  7. m.news.nate.com
  8. news.mtn.co.kr
  9. topdaily.kr
  10. news.nate.com
  11. newspim.com
  12. buffettlab.co.kr
  13. news.nate.com
  14. newspim.com
  15. news.nate.com
  16. m.thinkpool.com
  17. pharm.edaily.co.kr
  18. m.news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis